Ranbaxy To Introduce Inersan Brand In India And Nepal
Posted AtRanbaxy.com
Signs exclusive in-licensing
agreement with CD Pharma, the Indian affiliate of
US-based VSL Pharmaceuticals
First of its kind break-through
drug in the Dental segment
Gurgaon, Haryana, India,
March 18, 2008
Ranbaxy Laboratories Limited
(Ranbaxy) today announced an exclusive in-licensing
agreement with CD Pharma to market the INERSAN*
brand in India and Nepal. The patented product,
a probiotic preparation, is used for the treatment
of dental problems such as Periodontitis, Gingivitis
and Halitosis . Presently there is no particular drug
available for the treatment of this dental problem.
INERSAN , a natural biological product, shall be a
first-of-its-kind to be introduced in India.
Commenting on the development,
Sanjeev I. Dani, Senior Vice President and Regional
Director Asia & CIS, Ranbaxy, said “In the
post patent era, we are driven by the need to in-license
differentiated products and introduction of INERSAN
tablets consolidates Ranbaxy’s position in Dental
segment.” He also added that Periodontitis,
Gingivitis and Halitosis are common Dental problems
which if ignored, can lead to more serious complications.
Dental practitioners in India currently do not have
any specialized prescription product for these conditions
and INERSAN tablets address this need for the segment.”
Early-stage Periodontitis
(Gum Disease) is painful and causes swollen and bleeding
gums. This can lead to serious infection and eventually
may cause tooth loss if left untreated. Some dentists
recommend surgical options such as f lap surgery,
soft tissue grafting or bone grafting and guided tissue
regeneration.
Studies carried out over
the years have shown that gum disease can affect a
person’s overall health. Women with advanced
gum diseases are likely to give birth to an underweight
or pre-term baby while the ability of oral microbes
to cross the placental barrier can expose the fetus
to infection. Cardiac ailment patients have to be
more careful to avoid Periodontitis because the bacteria
from the mouth can cause clotting problems in the
cardiovascular system and increase the risk of fatal
heart attacks.
Kanwaldeep
Chadha, Country Manager of CD Pharma India & Director
Asia Pacific (VSL Pharmaceuticals Inc.) , while
speaking on the occasion said, “Internationally
INERSAN has shown good clinical results across trials
done in oral inflammatory conditions of different
etiologies. Clinical trials conducted in India have
also given encouraging results. We plan to introduce
trial-backed-first-of-it’s-kind probiotic products
in the near future.” He further added, “Probiotics
is a new concept in India and is yet to be completely
understood. Medical education is needed to create
awareness about Probiotics. It is critical to understand
that any probiotic food or drug has to have a bare
minimum quantity of bacteria to be effective.”
About Ranbaxy Laboratories
Limited :
Ranbaxy Laboratories Limited,
India ' s largest pharmaceutical company, is an integrated,
research based, international pharmaceutical company
producing a wide range of quality, affordable generic
medicines, trusted by healthcare professionals and
patients across geographies. Ranbaxy’s continued
focus on R&D has resulted in several approvals
in developed markets and significant progress in New
Drug Discovery Research. The Company’s foray
into Novel Drug Delivery Systems has led to proprietary
"platform technologies," resulting in a
number of products under development. The Company
is serving its customers in over 125 countries and
has an expanding international portfolio of affiliates,
joint ventures and alliances, ground operations in
49 countries and manufacturing operations in 11 countries.
About CD Pharma India Private
Ltd:
CD Pharma India Private Ltd.,
headquartered in New Delhi, is Asian Affiliate of
US based VSL Pharmaceuticals Inc., one of the leading
Research and Development Company dedicated to the
product development in the area of probiotics. The
Company is focused on the clinical research, product
development and strategic commercial partnering to
provide innovative and scientifically substantiated
options to consumers and health care providers. Strenuous
R& D efforts have led to the development of proprietary
products in the area of gastroenterology, oral care,
gynecology, dermatology, oncology, and neonatology
with proven efficacy and safety. The Company has been
delivering strong commitment for quality care to Indian
consumers and health care providers through collaborative
efforts with partners such as Ranbaxy.
INERSAN*
is a patented brand of VSL Pharmaceuticals Inc., USA
March 18, 2008 |
